The concept rests on a principle borrowed from evolutionary ecology. When cancer cells evolve resistance to a first-line drug, the molecular machinery they deploy often carries hidden costs or collateral vulnerabilities. A collateral sensitivity arises when adaptation to one drug increases susceptibility to another. The researchers hypothesized that if a second drug could exploit such a vulnerability, then applying selective pressure with chemotherapy would actively steer the tumor population into a corner: cells that resist chemotherapy become exquisitely sensitive to the second agent, leaving them nowhere evolutionarily to hide. This is the double-bind, a strategy first theorized in mathematical oncology but rarely demonstrated with a concrete drug pair and a validated treatment schedule.

To find such a pair, the team, led by Rena Emond of City of Hope and Jeffrey West of the Moffitt Cancer Center, worked with two ER+ breast cancer cell lines, MCF-7 and T-47D. Over six to eight months, they evolved sublines resistant to two common chemotherapies, paclitaxel and doxorubicin, by exposing cells to weekly pulses of each drug. They then screened thirty-seven candidate compounds, spanning FDA-approved oncology drugs, agents tested in clinical trials, and inhibitors of pathways linked to resistance. The screen measured whether each candidate preferentially killed resistant cells relative to their sensitive parents. Disulfiram, an inhibitor of aldehyde dehydrogenase, stood out: across all four chemotherapy-resistant line pairs, it showed dose-dependent toxicity that spared the sensitive parental cells, exactly the asymmetry a double-bind requires.

With disulfiram identified, the next question was whether combining it with chemotherapy produced true synergy, mere additivity, or antagonism. The researchers ran full checkerboard dose-response assays on both sensitive and resistant lines and analyzed the results with the MuSyC framework, which separates synergy into two components: synergistic potency, a shift in the half-maximal effective concentration, and synergistic efficacy, an increase in the maximum killing achieved at high doses of both drugs. The results were nuanced. In treatment-naive cells, the combination was largely neutral, meaning the two drugs acted additively rather than synergistically. In most resistant lines the additivity held, with one notable exception: doxorubicin-resistant MCF-7 cells displayed genuine synergistic potency with the combination. Importantly, antagonism was rarely observed, and the high-dose combination achieved maximal killing across every cell line and resistance background tested.

One curious finding emerged from the dose-response curves. Disulfiram alone behaved non-monotonically: intermediate doses killed more cells than the highest doses, producing a paradoxical dip in efficacy at high concentrations. When chemotherapy was added, this instability vanished, and the combination curve became smoothly dose-dependent. The authors suggest chemotherapy stabilizes disulfiram’s drug effect, an observation that underscores how combination contexts can rescue drugs whose monotherapy behavior is unpredictable. The team also notes that even additive combinations can be clinically valuable, a point increasingly recognized as trials of supposedly synergistic combinations often deliver benefits explainable by simple independent drug action.

Drug-drug interactions, however, tell only half the story. Tumors are ecosystems in which sensitive and resistant cells compete, cooperate, and modulate each other’s growth. To capture these dynamics, the researchers turned to the evolutionary game assay, a technique that quantifies frequency-dependent growth rates. They fluorescently labeled sensitive cells with one protein and resistant cells with another, then grew them as three-dimensional spheroids at initial resistant fractions of zero, twenty-five, fifty, seventy-five, and one hundred percent. Under untreated conditions, sensitive cells grew faster across all mixtures, revealing a fitness cost to resistance. Under chemotherapy, resistant cells held their advantage as expected. Under disulfiram, the picture flipped: resistant cells lost fitness to a far greater degree than sensitive ones, confirming the collateral sensitivity in a competitive, three-dimensional setting that more closely mimics the tumor microenvironment than flat culture dishes.

From these experiments the team built a game-theoretic mathematical model. Each cell type’s growth rate is described as a linear function of the population’s composition, yielding a four-parameter payoff matrix. Two derived quantities, the invasion fitnesses of sensitive and resistant cells when rare, determine the selection dynamics: whether sensitive cells dominate, resistant cells take over, the two coexist, or the system is bistable. The model also defines an overall tumor fitness, the long-term growth rate of the whole spheroid once selection reaches equilibrium. The critical prediction was unambiguous: continuous combination therapy with chemotherapy and a high dose of disulfiram drove tumor fitness to its most negative value, meaning the entire population, sensitive and resistant alike, would shrink rather than merely shift in composition.

The model then confronted a practical clinical question: should the two drugs be given together, or sequentially? Because the double-bind depends on resistance to the first drug, one might reasonably argue for chemotherapy first and disulfiram later. The team simulated alternating schedules with fast weekly and slower biweekly switching, always beginning with chemotherapy since disulfiram performs best once resistance has been selected. Across all parameterizations, the simulations predicted that combination therapy would outperform every sequential regimen. The researchers then tested this prediction directly in their spheroid system, treating mixed populations with twenty-five nanomolar doxorubicin and five hundred nanomolar disulfiram either continuously or in alternating schedules. The experiments confirmed the mathematics: combination treatment suppressed total cell count more effectively than any sequential strategy, across both cell lines and all initial resistant fractions. Interestingly, in MCF-7 cultures, leading a sequential schedule with disulfiram controlled growth better than leading with chemotherapy, but neither alternating approach matched the continuous combination.

The choice of disulfiram carries practical appeal beyond its evolutionary credentials. As an FDA-approved drug with decades of safety data, it can be repurposed without the lengthy development timeline of a novel molecule. Clinical trials have already explored disulfiram combinations in metastatic pancreatic cancer, treatment-refractory sarcoma, and recurrent glioblastoma, though the glioblastoma trial showed no significant survival benefit. Preclinical work suggests multiple mechanisms by which disulfiram might strike at chemo-resistant cells: it inhibits PI3K signaling, blocks ABC drug efflux pumps that drive multidrug resistance, suppresses NF-kB and epithelial-mesenchymal transition, undermines breast cancer stem cell self-renewal, and its copper-dependent metabolite induces p53-mediated apoptotic cell death. The present study did not pinpoint which of these mechanisms underlies the observed collateral sensitivity, and the authors flag mechanistic dissection as a priority for future work.

The researchers are careful about scope. These results come from cell lines and spheroids, not patients, and translating the double-bind into the clinic will require in vivo studies to establish optimal dosing, timing, and toxicity, particularly since disulfiram is unlikely to be administered alone and may behave differently in copper-containing combinations. Still, the study delivers something rarer than another drug pair: a validated, quantitative framework that integrates drug screening, evolutionary game assays, and mathematical modeling to predict which treatment schedule best suppresses resistance before a single patient is treated. If the evolutionary double-bind holds up in animal models and trials, the strategy could reframe how oncologists think about drug resistance, not as an inevitable failure of chemotherapy, but as a predictable vulnerability waiting to be exploited.

Subject of Research: Evolutionary double-bind combination therapy with disulfiram and chemotherapy to suppress drug resistance in ER+ breast cancer

Article Title: A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind

Article References: Emond, R., West, J., Grolmusz, V. K., Cosgrove, P. A., Nath, A., Anderson, A. R. A., & Bild, A. H. (2026). A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind. Molecular Systems Biology, 22(7), 1070-1096. https://doi.org/10.1038/s44320-026-00191-z

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00191-z

Keywords: ER+ breast cancer, drug resistance, disulfiram, chemotherapy, collateral sensitivity, evolutionary game theory, combination therapy, drug repurposing, mathematical modeling, spheroids, Molecular Systems Biology, cancer evolution